Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 1.00 |
| ▸ | ABL1 | P00519 | 6/20 | 1.00 |
| ▸ | ABL2 | P42684 | 6/20 | 1.00 |
| ▸ | PRKCA | P17252 | 1/20 | 0.71 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29406611 | 1.00 | EGFR (1.00) | EGFRABL1ABL2PRKCAKDR | |
| SCHEMBL27627681 | 0.95 | EGFR (0.91) | EGFRABL1ABL2PRKCAKDR | |
| SCHEMBL29795688 | 0.95 | EGFR (0.91) | EGFRABL1ABL2PRKCAKDR | |
| SCHEMBL2459209 | 0.86 | EGFR (1.00) | EGFRABL1ABL2PRKCAKDR | |
| SCHEMBL2461152 | 0.86 | EGFR (1.00) | EGFRABL1ABL2PRKCAKDR | |
| SCHEMBL2461133 | 0.84 | EGFR (1.00) | EGFRABL1ABL2PRKCAKDR | |
| SCHEMBL2460989 | 0.84 | EGFR (1.00) | EGFRABL1ABL2PRKCAKDR | |
| SCHEMBL2461158 | 0.84 | EGFR (1.00) | EGFRABL1ABL2PRKCAKDR | |
| SCHEMBL2464688 | 0.84 | EGFR (1.00) | EGFRABL1ABL2PRKCA | |
| SCHEMBL7494688 | 0.84 | EGFR (0.72) | EGFRABL1ABL2PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041137-B1 | PYRROLOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2011-09-28 | — | — | EP | claimed |
| US-6096749-A | ANTITUMOR, EPIDERMAL GROWTH FACTOR | NOVARTIS CORPORATION (US) | 2000-08-01 | — | — | US | claimed |
| WO-1998043973-A1 | INTERMEDIATE PRODUCTS AND METHOD FOR THE PRODUCTION OF PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 1998-10-08 | — | — | WO | claimed |
| EP-0682027-B1 | Pyrrolopyrimidine derivatives with antiproliferative action | CIBA GEIGY AG (CH) | 1997-10-15 | — | — | EP | claimed |
| WO-1997032589-A1 | COMBINATIONS FOR TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | claimed |
| WO-1997032604-A1 | ANTIPROLIFERATIVE COMBINATIONS, CONTAINING RAF-TARGETED OLIGONUCLEOTIDES AND CHEMOTHERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | claimed |
| EP-0682027-A1 | Pyrrolopyrimidine derivatives with antiproliferative action | CIBA-GEIGY AG (CH) | 1995-11-15 | — | — | EP | claimed |
| JP-8053454-A | — | — | None | — | — | JP | disclosed |
| US-20160051556-A1 | Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-02-25 | — | — | US | disclosed |
| US-20160051556-A1 | Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-02-25 | — | — | US | disclosed |
| WO-2014147246-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF CHRONIC LIVER DISEASES ASSOCIATED WITH A LOW HEPCIDIN EXPRESSION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2014-09-25 | — | — | WO | disclosed |
| US-8198266-B2 | Use of an EGFR antagonist for the treatment of glomerolonephritis | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2012-06-12 | — | — | US | disclosed |
| US-8198266-B2 | Use of an EGFR antagonist for the treatment of glomerolonephritis | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2012-06-12 | — | — | US | disclosed |
| WO-2008053270-A2 | USE OF AN EGFR ANTAGONIST FOR THE TREATMENT OF GLOMEROLONEPHRITIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2008-05-08 | — | — | WO | disclosed |
| US-20030201208-A1 | Dynamic superparamagnetic markers | KOCH, MARTIN (DK) | 2003-10-30 | — | — | US | disclosed |
| US-6096749-A | ANTITUMOR, EPIDERMAL GROWTH FACTOR | NOVARTIS CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| WO-1998043973-A1 | INTERMEDIATE PRODUCTS AND METHOD FOR THE PRODUCTION OF PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 1998-10-08 | — | — | WO | disclosed |
| EP-0682027-B1 | Pyrrolopyrimidine derivatives with antiproliferative action | CIBA GEIGY AG (CH) | 1997-10-15 | — | — | EP | disclosed |
| JP-H0853454-A | PYRROLOPYRIMIDINE HAVING PHARMACOLOGICAL ACTIVITY | CIBA GEIGY AG | 1996-02-27 | — | — | JP | disclosed |
| EP-0682027-A1 | Pyrrolopyrimidine derivatives with antiproliferative action | CIBA-GEIGY AG (CH) | 1995-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051556-A1 | Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression | HAMP, HDGF, TFRC | EGFR 17/4885ABL1 2514/4885ABL2 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.